Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Developing novel small molecule boosting agents for anti-cancer engineered T cell therapies

FY 2022-23

Summary
Immunotherapy is an emerging cancer therapy that uses a patient’s own immune cells to treat their cancer. Advancements in scientific technology now allow us to modify and train immune cells, such as T cells, to target and kill cancer cells. T cells provide the human body protection by surveilling and removing harmful cells from the body. A challenge within this treatment is that T cells require activation signals from their environment to survive, replicate, and kill cancer once they are delivered within the patient. Activation signals tend to be absent in a tumour environment, resulting in dysfunctional cells and less effective therapy. Some researchers approached this challenge by modifying the engineered T cells but observed toxic reactions. We may be able to address the current challenges by using a class of chemical compounds (“small molecules”) to provide the activation signals required for engineered T cell function. We identified Ferutinin, a plant-derived small molecule, as a promising drug candidate from an evaluation of 4000 compounds for their impact on engineered T cell function. We are interested in further investigating how Ferutinin and Ferutinin-like compounds enhance engineered T cell replication, survival, and tumour killing by combining T cell immunotherapy with Ferutinin in different tumour models. What we learn from this evaluation can help us to modify and improve the structure of Ferutinin to increase its engineered T cell boosting activity. We think investigating Ferutinin holds the promise of advancing cancer immunotherapies by introducing a novel drug that can improve engineered T cell killing, replication, and survival within the patient.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486498
Name
Adeel Zoya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing novel small molecule boosting agents for anti-cancer engineered T cell therapies
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Cancer; Cancer Immunotherapy; Drug Discovery; Engineered T Cells; Ferutinin; High Throughput Screening; Immuno-Oncology; Structure Activity Relationship; T Cell Activation
Abstract
Immunotherapy is an emerging cancer therapy that uses a patient’s own immune cells to treat their cancer. Advancements in scientific technology now allow us to modify and train immune cells, such as T cells, to target and kill cancer cells. T cells provide the human body protection by surveilling and removing harmful cells from the body. A challenge within this treatment is that T cells require activation signals from their environment to survive, replicate, and kill cancer once they are delivered within the patient. Activation signals tend to be absent in a tumour environment, resulting in dysfunctional cells and less effective therapy. Some researchers approached this challenge by modifying the engineered T cells but observed toxic reactions. We may be able to address the current challenges by using a class of chemical compounds (“small molecules”) to provide the activation signals required for engineered T cell function. We identified Ferutinin, a plant-derived small molecule, as a promising drug candidate from an evaluation of 4000 compounds for their impact on engineered T cell function. We are interested in further investigating how Ferutinin and Ferutinin-like compounds enhance engineered T cell replication, survival, and tumour killing by combining T cell immunotherapy with Ferutinin in different tumour models. What we learn from this evaluation can help us to modify and improve the structure of Ferutinin to increase its engineered T cell boosting activity. We think investigating Ferutinin holds the promise of advancing cancer immunotherapies by introducing a novel drug that can improve engineered T cell killing, replication, and survival within the patient.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Adeel, Zoya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~